Latest KFF Health News Stories
Medicamentos ya conocidos, y baratos, podrían ser clave para tratar covid
Hay medicamentos aprobados hace años que podrían investigarse en profundidad para tratar covid. Pero no hay interés porque no generarían grandes ganancias.
Scientists Seek Covid Treatment Answers in Cheap, Older Drugs
Philanthropies are funding studies of cheap, existing medications like the antidepressant fluvoxamine as covid treatments. But early hype about hydroxychloroquine and other repurposed drugs leaves researchers leery of hasty conclusions.
Analysis: How the US Invested in the War on Terrorism at the Cost of Public Health
After 9/11, as our defenses against international and bioterrorism hardened, our defenses against infectious diseases shrank. By the time a deadly virus arrived on our shores last year, nearly two-thirds of Americans were living in counties that spend more than twice as much on policing as they spend on public health.
KHN’s ‘What the Health?’: Getting Down to Work at HHS
After a bruising confirmation process, Xavier Becerra was sworn in as secretary of Health and Human Services this week. The Senate also confirmed the nominations of former U.S. Surgeon General Vivek Murthy to return to the post he held in the Obama administration, and former Pennsylvania health secretary Rachel Levine as assistant secretary for health. Levine is the first openly transgender person to receive Senate confirmation. Meanwhile, questions continue to swirl around the AstraZeneca covid vaccine, which some public health experts worry will create more hesitancy toward other vaccines.
Birx Joins Air-Cleaning Industry Amid Land Grab for Billions in Federal Covid Relief
Air-cleaning companies with limited oversight are targeting a growing market of schools desperate for covid-19 protection. Donald Trump’s former covid adviser lands with one that built its business, in part, on ozone-emitting technology.
The Hype Has Faded, but Don’t Count Out Convalescent Plasma in Covid Battle
The once-promising therapy that infuses blood plasma from recovered covid-19 patients into newly infected people, theoretically to boost immunity, has suffered setbacks. But some proponents say it’s too early to abandon the treatment.
To Extract More Doses per Vial, Vaccinators Put Squeeze on FDA to Relax Vaccine Handling Advice
Although vaccine supply is ramping up, the supply gap puts pressure on vaccinating teams to extract every drop they can. Some are asking the FDA to waive guidance against extracting vaccine from two vials with the same needle. It’s worth a shot.
Pfizer’s Newest Vaccine Plant Has Persistent Mold Issues, History of Recalls
After nearly a decade’s worth of federal inspections, reprimands and corrective action plans, has Pfizer fixed the facility that will be filling vials of its covid vaccine?
Miedo a las jeringas, obstáculo inesperado en los esfuerzos de vacunación contra covid
La desinformación que se difunde en las redes sociales a menudo incorpora imágenes de jeringas gigantes, que aterra a fóbicos y los aleja de las dosis.
Ouch! Needle-Phobic People Scarred by So Many Images of Covid Shots
The pictures are on the nightly news, on billboards, bus stop posters and all over social media. How can people who fear needles manage to get their covid shots?
Why AstraZeneca and J&J’s Vaccines, In Use Elsewhere, Are Still on Hold in America
Covid has pressed the Food and Drug Administration into its fastest vaccine reviews ever — which are still painfully slow, critics say.
Have a Case of a Covid Variant? No One Is Going to Tell You
As experts race to get an approved test for covid variants, officials are severely restricted from sharing information about the cases. That makes it harder to protect others.
KHN’s ‘What the Health?’: All About Budget Reconciliation
Even while the Senate is busy with Donald Trump’s impeachment trial, the House has gotten down to work on a covid relief bill using the budget reconciliation process. Meanwhile, the watchword for covid this week among the public is confusion — over masks, vaccines and just about everything else science-related. Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also this week, the panelists recommend their favorite “health policy valentines” along with their favorite health policy stories they think you should read, too.
With U.S. cases skyrocketing, demand for Gilead’s dark horse antiviral is only growing. Biden appointees propose potential legal tactics to tamp down the price for patients.
COVID Vaccines Appear Safe and Effective, but Key Questions Remain
The federal government expects vaccinations to be available to everyone who wants them by summer — though glitches are inevitable. If enough of us get vaccinated, we could wave goodbye to the pandemic in 2021.
Las vacunas de COVID parecen ser seguras y efectivas, pero todavía hay preguntas
Una encuesta publicada en diciembre mostró que el 45% de los encuestados están adoptando un enfoque de “esperar y ver qué pasa” con la vacunación.
Inside the First Chaotic Days of the Effort to Vaccinate America
After missteps in Washington, each state and county is left to juggle where to send vaccines first and how to get them to each nursing home, hospital local health department and even school.
Desafío en hospitales: a qué trabajadores de salud vacunar primero contra COVID
Se aconseja a los hospitales que cubran a los miembros de su fuerza laboral con mayor riesgo, pero deben decidir exactamente quiénes serán mientras no haya dosis suficientes.
Hospitals Scramble to Prioritize Which Workers Are First for COVID Shots
Even as the federal Food and Drug Administration engaged in intense deliberations ahead of Friday’s authorization of the nation’s first COVID vaccine, and days before the initial doses were to be released, hospitals have been grappling with how to distribute the first scarce shots. Their plans vary broadly.
Demand for COVID Vaccines Expected to Get Heated — And Fast
With two vaccines against coronavirus disease poised for release within weeks, experts say they expect attitudes to shift dramatically from hesitancy to “Beanie Baby”-level urgency.
